The server is under maintenance between 08:00 to 12:00 (GMT+08:00), and please visit later.
We apologize for any inconvenience caused
Login  | Sign Up  |  Oriprobe Inc. Feed
China/Asia On Demand
Journal Articles
Laws/Policies/Regulations
Companies/Products
Bookmark and Share
Experiences of CD5+ Diffuse Large B-cell Lymphomas with Rituximab-containing Therapy and Salvage Autologous Hematopoietic Stem Cell Transplantation Treatment Failure
Pages: 201-205
Year: Issue:  3
Journal: Journal of Basic and Clinical Oncology

Abstract: 目的 分析原发性CD5+弥漫大B细胞淋巴瘤(DLBCL)的特点及其特殊性.方法 对1例初诊时病理漏检CD5的原发性CD5+ DLBCL患者的诊疗过程进行总结,并复习相关文献.结果 本例初诊和复发均按照NCCN指南推荐进行,分别选用含有利妥昔单抗的标准剂量一线、二线化疗方案.并在二次复发时行挽救性自体造血干细胞移植,仍无法阻止病情进展,最终在移植后1 a内死亡.结论 原发性CD5+ DLBCL预后差,加入利妥昔单抗的化疗方案治疗不能改善其生存,挽救性自体造血干细胞移植亦无法改善其预后.
Related Articles
No related articles found